Member Info for Hurst10

Indeed !

Well let us see what July will bring and 300 will indeed be achieved prior to AVA6000 trial news update.
They might have to Have another Investor day.
News flow will be quite something going forward.
There might be shorts out there, hence some of the posts, however I do hope they have the borrowing facility in place, as the prime broker will find them selves short of stock to settle trades going forward.

As quoted before by the management, airlines, hotels, Airports and large corporate organisations domestically and abroad.
Believe we will see very shortly confirmation of the above from foreign governments and businesses. Higher margins not to
Forget.
We still only have around 5% fully vaccinated!
Avacta is now on the radar screen very much abroad now, through their new distribution partner.
Once we have further evidence, in this country,why the FDA banned Innova and why Innova had to write to users of Innova in the US, asking them send it back ( using pre paid envelope provided by Innova ) as Innova stated in the enclosed letter, the LFT was not safe!!!

client of mine have just told me, the whole of his daughter?s year been sent home, because of one case!

https://www.washingtonpost.com/world/2021/07/06/coronavirus-latest-updates/

Almost 500,000 shares bought in post close

As mentioned before the Asian market will be an important market for testing, as at the moment it is virtually non existing.
:
The world’s fourth most populous nation has seen its daily caseload more than quadruple in less than a month and its tally stands at 2.3 million cases and 61,140 deaths.
But that figure is widely believed to be a severe undercount because of low testing and poor tracing measures.
Indonesia’s overwhelmed healthcare system has been teetering on the brink of collapse as jammed hospitals turned away patients, forcing desperate families to hunt for oxygen tanks to treat the sick and dying at home.

From today’s statement from Miton micro cap results:
Whilst economic conditions were challenging for some companies during the global pandemic, for others the nature of change offered them much greater potential than before. In the case of Avacta for example, they found their affimer technology which may significantly reduce the side effects of chemotherapy in time, was also potentially very suited to use in lateral flow tests for Covid. Synairgen found that their treatments that helped asthmatics combat the cold virus, turned out to be very helpful to lessen the disease for those with shortness of breath due to Covid.

PM “ rather than sending the children home, is to introduce testing at the schools”

Let us see Monday

Look at authors of the study:? John Hopkins School of Medicine ?
One of them

Authors of the study in the June 30, 2021, Journal of Infectious Diseases, are researchers at the University of Illinois at Urbana-Champaign (UIUC); University of Massachusetts Medical School, Worcester; Johns Hopkins School of Medicine, Baltimore; and NIBIB.

NIH-funded screening study builds case for frequent COVID-19 antigen testing | National Institutes of Health (NIH
https://www.nih.gov/news-events/news-releases/nih-funded-screening-study-builds-case-frequent-covid-19-antigen-testing
Buy more before the week end!!

NIH study suggests antigen tests and PCR tests are equally effective in detecting COVID-19

Article to follow shortly

The highly contagious Delta variant of the coronavirus is gaining ground in Italy, the National Health Institute (ISS) said on Friday, releasing data showing it accounted for some 22.7% of cases as of June 22.

In the previous such survey based on data from May 18, the Delta variant represented just 1% of cases. By contrast, the Alpha variant accounted for 57.8% of cases as of June 22 against a previous 88.1%.

"In Italy, where the vaccination campaign has not yet achieved sufficient coverage, the spread of more transmissible variants may have a significant impact", the institute said.

The Delta variant, first detected in India in December 2020 year, has spread to about 100 countries and the World Health Organisation warned recently that it could soon become the dominant form of the virus.

The ISS said its survey did not include all variant cases but only those detected on the day it was carried out. It added that the Kappa variant had not been found on that day despite several cases being signalled at other times.

The data also showed a rise in the Gamma variant, first identified in Brazil, to 11.8% of cases from 7.3% in the past survey.

Italy has registered 127,587 deaths linked to COVID-19 since its outbreak emerged in February last year, the second-highest toll in Europe after Britain and the eighth-highest in the world. The country has reported 4.26 million cases to date.

Studies released in Britain last month showed the Delta variant doubled the risk of hospitalisation, but that two doses of vaccine provided strong protection. Some 32.2% of Italians are fully vaccinated, while 25.6% are awaiting a second dose.

BA cargo plane 737 in the water off Hawaii

Nice prints at 185.40 post market

PM just quoted in interview “ extra precautions post COVID 17/7 dead line might be needed”!!

With current capacity Avacta will be able to do 30+30 mill a month, but the are in talks for further expansion.

POINT Biopharma Debuts as Publicly Traded
Next-Generation Radiotherapeutics Company
Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”

Gross proceeds from the transaction totaled approximately $286.7 million
June 30, 2021 –INDIANAPOLIS, INDIANA – POINT Biopharma Inc. (“POINT”), a company accelerating the discovery, development and global access to radiopharmaceuticals, today announced the completion of its business combination with Therapeutics Acquisition Corp., d/b/a Research Alliance Corp. I (Nasdaq: RACA) (“RACA”), a special purpose acquisition company (“SPAC”), sponsored by RA Capital Management. POINT Biopharma Global Inc. (“New POINT”), the resulting combined company, will commence trading shares of its common stock on the Nasdaq Capital Market (the “NASDAQ”) under the ticker symbol “PNT” on July 1, 2021.

The shareholders of RACA approved the transaction at a special meeting held on June 29, 2021. The transaction was previously approved by POINT’s shareholders. New POINT’s management team will be led by Chief Executive Officer Joe McCann, who previously served as POINT’s Chief Executive Officer.

“We are excited to be entering the public markets at a time when innovative radiopharmaceuticals have gained so much momentum and are being recognized as potential options for many types of cancer, including large indications such as prostate cancer. Looking ahead, we are working diligently to complete our two Phase 3 studies in prostate and neuroendocrine cancers, qualify of our manufacturing facility in Indiana, continue to build a robust radioisotope supply chain and advance our pipeline of therapeutic pre-clinical programs, including our Fibroblast Activation Protein-a, towards the clinic, in combination with alpha and beta emitting radioisotopes” said Dr. Joe McCann. “We want to thank our entire team, our new and existing shareholders, and all those involved in making this transaction a success. We look forward to bringing the next-generation of precision oncology medicines to patients.”

"To date, POINT has demonstrated their deep expertise in advancing a pipeline of novel radio-pharmaceuticals to improve current standard of care for patients with little or no therapeutic options,” said Peter Kolchinsky, Chief Executive Officer of RACA and Managing Partner at RA Capital Management. “We believe that the Company now has the capital resources required to advance their late stage radioligand therapies towards commercialization and continue to develop their early stage pipeline, both of which have the potential to meaningfully improve the prognosis and quality of life of patients.”

Summary of Transaction

On March 15, 2021, POINT entered into a definitive business combination agreement with RACA, a SPAC, sponsored by RA Capital Management, that was created for the purpose of entering into a business combination with a selected biopharmaceutical company and bringing the

Radio therapy